0001564590-21-043717.txt : 20210812 0001564590-21-043717.hdr.sgml : 20210812 20210812103549 ACCESSION NUMBER: 0001564590-21-043717 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20210812 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210812 DATE AS OF CHANGE: 20210812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Talaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001827506 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40384 FILM NUMBER: 211165953 BUSINESS ADDRESS: STREET 1: 201 E. JEFFERSON ST., SUITE 110B CITY: LOUISVILLE STATE: KY ZIP: 40202 BUSINESS PHONE: 502-569-1059 MAIL ADDRESS: STREET 1: 201 E. JEFFERSON ST., SUITE 110B CITY: LOUISVILLE STATE: KY ZIP: 40202 8-K 1 tals-8k_20210812.htm 8-K tals-8k_20210812.htm
false 0001827506 Common Stock, $0.0001 par value per share 0001827506 2021-08-12 2021-08-12

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2021

 

TALARIS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-40384

83-2377352

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

Talaris Therapeutics, Inc.

570 S. Preston St

Louisville, KY 40202

(Address of principal executive offices, including zip code)

(502) 398-9250

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trade

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.0001

par value per share

 

TALS

 

The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2021, Talaris Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2021 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:

 

Exhibit No.

 

Description

 

 

 

99.1

  

Press Release issued by Talaris Therapeutics, Inc. on August 12, 2021.

 

 

 

104

  

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Talaris Therapeutics, Inc.

 

 

 

 

Date: August 12, 2021

 

By:

  /s/ Scott Requadt

 

 

 

  Scott Requadt

 

 

 

  President and Chief Executive Officer

 

 EX-99.1 2 tals-ex991_6.htm EX-99.1 tals-ex991_6.htm

Exhibit 99.1

 

Talaris Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update

On track to provide FREEDOM-1 initial clinical update, initiate FREEDOM-2 and FREEDOM-3 trials, and to disclose additional indication for FCR001 before year-end

 

BOSTON, MA, and LOUISVILLE, KY, August 12, 2021 –  Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today reported financial results for the three- and six-month periods ended June 30, 2021, and provided an update on its business.  

 

“As we enter the second half of 2021, we remain on track to provide the first clinical update on our first FREEDOM-1 patients,” stated Scott Requadt, Chief Executive Officer of Talaris. “Based on what we observed in our Phase 2 trial, we believe that chimerism, as early as three months post-transplant, has the potential to be highly predictive of establishing durable tolerance to the donated organ without chronic immunosuppression. We are also continuing to advance the rest of our pipeline as we plan for two phase 2 clinical trial initiations in FCR001 in delayed tolerance induction (FREEDOM-2) and in patients with a severe form of scleroderma (FREEDOM-3).  We also expect to announce an additional indication for FCR001 before the end of this year.”  

 

Corporate Highlights

 

 

•

Initial safety and chimerism data from the Phase 3 FREEDOM-1 trial to be provided later this year. FREEDOM-1 is a randomized, controlled, open-label Phase 3 registrational trial of FCR001 in 120 adult living donor kidney transplant (“LDKT”) recipients in the United States. The primary endpoint of FREEDOM-1 is the proportion of living donor kidney transplant recipients treated with FCR001 who are free from chronic immunosuppression, without proven biopsy rejection (“BPAR”), at month 24 post-transplant. The Company plans to update investors on both safety and chimerism status of evaluable patients who have been followed for at least three months since dosing. Chimerism refers to a condition whereby both the donor’s and the recipient’s hematopoietic stem cells (“HSCs”) co-exist in the recipient’s bone marrow.  In the Company’s Phase 2 trial, achievement and maintenance of >50% donor T-cell chimerism in the transplant recipient at three-, six- and twelve months after administration of FCR001 all correlated strongly with the transplant recipient’s ability to durably discontinue chronic immunosuppression approximately one year after transplant, without subsequent graft rejection.

 

 

•

Added new clinical sites to its Phase 3 FREEDOM-1 trial. The Company has expanded its clinical trial footprint to 14 active sites in the United States. The Company’s clinical trial sites are geographically dispersed across the United States and are all recognized as transplant centers of excellence.

 

Program Updates and Milestones

 

 

•

FCR001 in living donor kidney transplant (LDKT). The Company’s lead product candidate, FCR001, is currently in a randomized, controlled, open-label, multi-center Phase 3 (FREEDOM-1) trial in the United States. FCR001 has been granted Regenerative Medicine Advanced Therapy (“RMAT”) and Orphan Drug designations by the U.S. Food and Drug Administration (“FDA”) in this indication.

 

 

•

FCR001 in delayed tolerance induction. The Company remains on track to initiate a Phase 2 (FREEDOM-2) trial for FCR001 in delayed tolerance induction in the fourth quarter of 2021. In FREEDOM-2, the Company will evaluate the potential for FCR001 to induce immune tolerance to a transplanted kidney in patients who received a kidney transplant from a living donor up to a year prior to administration of FCR001.

 

 

•

FCR001 in scleroderma. The Company remains on track to initiate its first clinical trial in autoimmune diseases with its FREEDOM-3 trial in the fourth quarter of 2021. FREEDOM-3 is a multi-center, single-arm, open-label, proof-of-concept Phase 2 trial assessing the safety and efficacy of FCR001 in adults with a severe form of scleroderma at risk for organ failure.

 

 

•

Potential applications in deceased donor organ transplant. The Company continues to perform preclinical research to explore the feasibility of developing a product candidate similar to FCR001 from bone marrow procured from deceased organ donors, for potential administration to recipients of a deceased donor organ transplant.

 

 

•

FCR001 in non-malignant blood, immune and metabolic disorders. The Company remains on track to announce an additional target indication for FCR001 relating to a severe non-malignant blood, immune or metabolic disorder before the end of 2021.

 

Second Quarter 2021 Financial Results

 

 

•

Cash, Cash Equivalents and Marketable Securities: Talaris finished the second quarter of 2021 with $266.2 million in cash, cash equivalents and marketable securities compared with $149.5 million as of December 31, 2020. Current cash and cash equivalents are expected to fund pipeline development and operations into 2025.

 

 

•

R&D Expenses: Research and development expenses increased to $7.6 million in the second quarter of 2021, up from $3.4 million in the second quarter of 2020. The increase in research and development expenses was primarily due to an increase in employee headcount necessary to support the growth of the Company’s research and development efforts, increased clinical trials costs and an increase in facilities and other expenses.

 

 

•

G&A Expenses: General and administrative expenses totaled $3.5 million in the second quarter of 2021, up from $1.3 million in the second quarter of 2020, primarily due to an increase in employee headcount, increased professional fees and an increase in facilities and other expenses.

 

 

•

Net Loss: The Company reported a net loss of $11.4 million, or $0.41 per share, in the second quarter of 2021, compared with a net loss of $4.7 million, or $0.73 per share, in the second quarter of 2020.

 

 

 

About Talaris Therapeutics

Talaris Therapeutics, Inc. is a late-clinical stage biopharmaceutical company developing investigational, one-time, allogeneic cell therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, MA, and at its cell processing facility in Louisville, KY.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Talaris Therapeutics, Inc.’s (“Talaris,” the “Company,” “we,” or “our”) strategy, business plans and focus; the progress and timing of the preclinical and clinical development of Talaris’ programs, including FCR001 and FCR002; expectations regarding the timing and data from the planned clinical update of FREEDOM-1; expectations regarding Talaris’ use of capital, expenses and other financial results during 2021 and in the future, and its ability to fund operations into 2025. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

 

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which the Company has operations or does business, as well as on the timing and anticipated timing and results of its clinical trials, strategy and future operations, including the expected timing and results from FREEDOM-1, the planned initiation of FREEDOM-2 and FREEDOM-3, the planned initiation and timing of IND-enabling studies of FCR001 and FCR002 in deceased donor transplants and the announcement of an additional indication for FCR001; the Company’s expectations regarding its management hires; the risk that the results of Talaris’ clinical trials may not be predictive of future results in connection with future clinical trials; the Company’s ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of Talaris’ planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Talaris’ views only as of today and should not be relied upon as representing our views as of any subsequent date. Talaris explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

 

Media Contact

Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783

 

Investor Contact

Chris Brinzey
Westwicke, an ICR Company
chris.brinzey@westwicke.com
(339) 970-2843

 

TALARIS THERAPEUTICS, INC (TALS)

Statements of Operations

(Unaudited, in thousands, except share and per share amounts)

 

 

 

Three months ended June 30,

 

 

 

2021

 

 

2020

 

 

 

(in thousands)

 

Operating expenses

 

 

 

 

 

 

 

 

Research and development

 

$

7,570

 

 

$

3,402

 

General and administrative

 

$

3,487

 

 

$

1,335

 

Total operating expenses

 

 

11,057

 

 

 

4,737

 

Loss from operations

 

 

(11,057

)

 

 

(4,737

)

Interest and other income (expense), net

 

$

(295

)

 

$

74

 

Net loss attributable to common stockholders

 

$

(11,352

)

 

$

(4,663

)

Net loss per common share, basic and diluted

 

$

(0.41

)

 

$

(0.73

)

Weighted average number of common shares outstanding used in

    computation of net loss per common share, basic and diluted

 

$

27,373,165

 

 

$

6,397,025

 

 

 

Balance Sheets Selected Financial Data

(Unaudited, in thousands)

 

 

 

As of June 30, 2021

 

 

As of December 31, 2020

 

Cash, cash equivalents and marketable securities

 

$

266,220

 

 

$

149,488

 

Working capital

 

 

265,809

 

 

 

147,347

 

Total assets

 

 

272,814

 

 

 

152,778

 

Other liabilities

 

 

800

 

 

 

1,369

 

Total liabilities

 

 

5,461

 

 

 

4,774

 

Total convertible preferred stock and stockholders’ deficit

 

 

267,353

 

 

 

148,004

 

 

 

 GRAPHIC 3 gwpe3mueayuh000003.jpg GRAPHIC begin 644 gwpe3mueayuh000003.jpg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gwpe3mueayuh000004.jpg GRAPHIC begin 644 gwpe3mueayuh000004.jpg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gwpe3mueayuh000002.jpg GRAPHIC begin 644 gwpe3mueayuh000002.jpg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gwpe3mueayuh000001.jpg GRAPHIC begin 644 gwpe3mueayuh000001.jpg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tals-20210812.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 8 tals-20210812_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trade Symbol(s) Trading Symbol Name of each exchange on which registered Security Exchange Name EX-101.PRE 9 tals-20210812_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 tals-8k_20210812_htm.xml IDEA: XBRL DOCUMENT 0001827506 2021-08-12 2021-08-12 false 0001827506 Common Stock, $0.0001 par value per share 8-K 2021-08-12 TALARIS THERAPEUTICS, INC. DE 001-40384 83-2377352 570 S. Preston St Louisville KY 40202 502 398-9250 false false false false TALS NASDAQ true false XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 12, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 12, 2021
Entity Registrant Name TALARIS THERAPEUTICS, INC.
Entity Central Index Key 0001827506
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-40384
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 83-2377352
Entity Address, Address Line One 570 S. Preston St
Entity Address, City or Town Louisville
Entity Address, State or Province KY
Entity Address, Postal Zip Code 40202
City Area Code 502
Local Phone Number 398-9250
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Common Stock, $0.0001 par value per share
Trade Symbol(s) TALS
Name of each exchange on which registered NASDAQ
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( '94#%,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !V5 Q3,!E<,N\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M3L,P#(=?!>7>NFD'0E&7"]-.("$Q"<0M2KPMHOFCQ*C=V].6K1."!^ 8^Y?/ MGR6W.@H=$CZG$#&1Q7PSN,YGH>.:'8FB ,CZB$[ED/ M=4"HJ^H.')(RBA1,P"(N1"9;HX5.J"BD,][H!1\_4S?#C ;LT*&G#+SDP.0T M,9Z&KH4K8((1)I>_"V@6XES]$SMW@)V30[9+JN_[LF_FW+@#A[>GQY=YW<+Z M3,IK'']E*^@4<[_A*-+=BQ=\GUQ]^5V$7C-W; M?VQ\$90M_+H+^0502P,$% @ =E0,4YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !V5 Q3.]62,&<$ #X$ & 'AL+W=O?0L/THIU)P!80R YAQB'972;9+(W9[K2=7@A;8$UDRY7D M0-Z^1X;8=.L<,],;L(S.[T]'TG]D)ENEGTS"N26[5&;FJI-8FW_H]4R4\)29 MKLIY!K^LE4Z9A:;>]$RN.8O+H%3VJ.==]%(FLLYT4MY;Z.E$%5:*C"\T,46: M,OURS:7:7G7\SNN-1[%)K+O1FTYRMN$AM]_RA896KU*)162=!(.O9S[C4CHEX/C[(-JI MGND"CZ]?U3^6@X?!K)CA,R6_B]@F5YUQA\1\S0II']7V,S\,J 2,E#3E)]GN M^PX&'1(5QJKT$ P$J<,LFTZTVA+M>H.: MNRB'6D8#G,C[P7I&X)!L>D2GYX1ZE'_W^$]8*L :05(2[W^&WHS]?F2\Z81XN'C\SL$8E!!#%"5 CBDN*C9)LF"CQ^S:3A",>P MXAB>EHP%UT*Y-1 36$F-><&57F?^_;MW+7-_4;%=H(J']?C(-\+-/D ^L+21 M#-=9!O?!XSPDR\^WC\'B]MMR/@O/R/QAUD4@1Q7DZ!3(&>10,PF;)^8[W($B;4B-*:]TNOB0D7:]L#OE>[H'<*UDZA M'_F:-><.EQR./!)VR0)T+(PTM!AH70]\W-!_!)VY%DST4FV;RS N=Z\*89Z% ME.@&J:N$CYO[CW35.EQH]2RRJ#F/N.;=[QA:723\DZI$A;90QH(1_R'RMS<' MKCCPH(!A;'5M\'%++R%I46GGJ$D!QDP:'.8\@/1SVU_[ "F=&. U_7:^;YZ]%KY7LZ%".F_1_ MR.;&%$#6"HC+M@+6MD]QCUX*"Z58]U_ E^8 M.[L:(OD:E+SN"(3U_C5[W[ J+U]M5\K"BW)YF7!(HG8=X/>U4O:UX=Z6JS\[ MIO\ 4$L#!!0 ( '94#%.?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND M,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0& M@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&- M!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+ MY2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'D ML\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y M+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^ M7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM! M)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z M!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C M$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7 M,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( '94#%.7BKL

-8?2 M0$3;8T.P6BP^0"X99K>]9!:GH_ 0 M/ ( \ !X;"]W;W)K8F]O:RYX;6R-49:E ML@9OTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L M@!W".?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR M#'9 C.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/73>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0 ( '94#%,D'INB MK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S , MA:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@ MMO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*< M//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P M6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04 " !V5 Q3 M99!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\2 M95LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&P MZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5 M,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*I ML0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U M[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ M 5!+ 0(4 Q0 ( '94#%,'04UB@0 +$ 0 " 0 M !D;V-0&UL4$L! A0#% @ =E0,4S 97#+O *P( M !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% M @ =E0,4YE&PO=V]R:W-H965T&UL4$L! A0#% M @ =E0,4Y^@&_"Q @ X@P T ( !JPP 'AL+W-T>6QE M&PO=V]R:V)O;VLN>&UL4$L! A0#% @ M=E0,4R0>FZ*M ^ $ !H ( !W!$ 'AL+U]R96QS+W=O M9(9 0 SP, !, M ( !P1( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D ,"0 ^ @ "Q0 end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports tals-8k_20210812.htm tals-20210812.xsd tals-20210812_lab.xml tals-20210812_pre.xml tals-ex991_6.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tals-8k_20210812.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tals-8k_20210812.htm" ] }, "labelLink": { "local": [ "tals-20210812_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "tals-20210812_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "tals-20210812.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tals", "nsuri": "http://talaristx.com/20210812", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tals-8k_20210812.htm", "contextRef": "C_0001827506_20210812_20210812", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tals-8k_20210812.htm", "contextRef": "C_0001827506_20210812_20210812", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trade Symbol(s)" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://talaristx.com/20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 19 0001564590-21-043717-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-043717-xbrl.zip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end